A phase Ib clinical trial using an attenuated version of an immunogenic peptide of Folate binding protein (FBP) in combination with wild-type peptide in disease-free breast and ovarian cancer patients after standard therapies elicited better immune response compared to wild-type peptide alone (NCT02019524) [73]. Here, FOLR1 is linked to ovarian cancer.